CHARLOTTESVILLE, VA and ATHENS, Greece, Dec. 1 /CNW/ - Biovista Inc. today announced the signing of a new collaboration agreement with the Thalassaemia International Federation (TIF) for the installation and support of its JAnaemia patient record management system. JAnaemia, which has been customized, in this case for beta thalassaemia patients, will be initially installed at the New General and the Makarios hospitals in Nicosia, Cyprus.
"We are very pleased that the TIF selected JAnaemia as its patient record management system amongst some very worthy competitors," said Andreas Persidis, Ph.D., CEO of Biovista. "We are confident that JAanemia will offer doctors and other medical and research staff of the hospitals a resource that will help them provide better care to patients and ultimately understand this challenging disease better", said Spyros Deftereos, MD, Ph.D., VP Drug Discovery.
"The TIF is glad to have selected JAnaemia as the system that will help medical staff at our two hospitals, collect, manage and analyze patient records in a systematic way that will hopefully lead to better care for beta-thalassaemia patients", said Dr. Androulla Eleftheriou, Executive Director of TIF. "Once the deployment at these two pilot hospitals is complete, we plan to invite other thalassaemia organizations, both in Cyprus and abroad, to join" Dr. Eleftheriou added.
About Biovista and the JAnaemia platform
Biovista applies high-throughput discovery efforts to finding solutions for commercially relevant unmet medical needs. Biovista's technology platform allows the company's experts to perform mechanism-of-action based analyses and systematically assess clinical outcomes in any therapeutic area of interest. The company is presently using this platform to develop its own pipeline of repositioned drugs in areas such as CNS, cardiovascular disease, oncology and auto-immune diseases. JAnaemia is the part of Biovista's platform that focuses on patient record management. It is a modular system that can include customer selected specific modules (such as Cardiology, and endocrinology) that optimize the system's performance for specific diseases of interest. JAnaemia has already been used in a research context for the determination of echocardiographic indices that predict clinical course in patients with beta-thalassemia.
SOURCE BIOVISTA INC.
For further information: For further information: Dr. Spyros Deftereos, VP DD, Biovista, +30-210-9629848, email@example.com; or Dr Androulla Eleftheriou, Executive Director, +357-22-319-129, firstname.lastname@example.org